[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-diabetes-insipidus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-diabetes-insipidus":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100578224","phase-2-effects-of-intranasal-oxytocin-on-sexual-well-being-in-patients-with-arginine-vasopressin-deficiency-and-healthy-controls-100578224",false,"NCT06808516","Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls","The OxyPLEASURE Study - Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - a Double-blind Randomized Placebo-controlled Crossover Trial","OxyPLEASURE","Inclusion Criteria for healthy controls:\n\n* Adult healthy volunteers aged 18 years and above\n* Matched for age, sex, BMI, and menopause\u002Fhormonal contraceptives to patients\n* No medication, except hormonal contraception\n* At least mild impairment in sexual function and satisfaction, defined as an ASEX-score ≥10 points and an NSSS-S score ≤ 48 points\n* Only Part A: Participants must be sexually active (at least once a week sexual intercourse) and in a current partnership for at least 6 months\n\nInclusion criteria for patients:\n\n* Adult patients aged 18 years and above, with a confirmed diagnosis of AVP deficiency based on established criteria\n* Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies\n* At least mild impairment in sexual function and satisfaction, defined as an ASEX-score ≥10 points and an NSSS-S score ≤ 48 points\n* Only Part A: Participants must be sexually active (at least once a week sexual intercourse) and in a current partnership for at least 6 months\n\nExclusion Criteria:\n\n* Pregnancy and breastfeeding within the last eight weeks\n* Participation in a trial with investigational drugs within 30 days\n* Active substance use disorder within the last six months\n* Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n* Current or previous psychotic disorder (e.g., schizophrenia)",true,"ALL","18 Years",{"count":21,"type":22},42,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.",[28,29,30],"Arginine Vasopressin Deficiency","Central Diabetes Insipidus","Oxytocin Deficiency",[32,33],"Nasal oxytocin","Sexual Well-Being","RECRUITING","2025-09-29",{"date":37,"type":38},"2025-10-03","ACTUAL",{"date":40,"type":38},"2025-07-01",{"date":42,"type":22},"2026-12",{"name":44,"class":45},"University Hospital, Basel, Switzerland","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":46},"100576777","plasma-oxytocin-changes-in-response-to-low-dose-mdma-vs-placebo-in-patients-with-arginine-vasopressin-deficiency-and-healthy-controls-100576777","NCT06789705","Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls","Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - the OxyMAX Study","OxyMAX","Inclusion criteria patients:\n\n1\\. Adult patients with confirmed diagnosis of Arginine Vasopressin deficiency (central diabetes insipidus)2 or with only anterior pituitary deficiency\n\nInclusion criteria healthy controls:\n\n1. Adult healthy controls\n2. Matched for age, sex, Body mass index, and oestrogen replacement\u002Fmenopause\u002Fhormonal contraceptives to patients\n3. No medication, except hormonal contraception\n\nExclusion Criteria:\n\n1. Participation in a trial with investigational drugs within 30 days\n2. Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months\n3. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n4. Tobacco smoking \\>10 cigarettes\u002Fday\n5. Cardiovascular disease (coronary artery disease, heart failure Left ventricular ejection fraction \\\u003C40%, stroke in the last 3 months, atrial fibrillation\u002Fflatter, Wolff-Parkinson-White-Syndrome)\n6. Uncontrolled arterial hypertension (\\>140\u002F90 mmHg) or hypotension (\\\u003C85mmHg)\n7. Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)\n8. Psychotic disorder in first-degree relatives\n9. Regular intake of selective serotonin reuptake inhibitors or Monoamine oxidase inhibitors\n10. Pregnancy and breastfeeding\n11. Diagnosed Chronic Kidney Disease \\> grade III (glomerular filtration rate \\\u003C 30ml\u002Fmin)\n12. Diagnosed liver cirrhosis or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range",{"count":56,"type":22},24,[58],"NA","The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients. This study will confirm previously published data and provide important safety data with low-dose MDMA stimulation testing.",[29],[62,63,64],"MDMA","oxytocin","arginin vasopressin","2025-02-18",{"date":67,"type":38},"2025-02-19",{"date":69,"type":38},"2025-01-27",{"date":42,"type":22},{"name":44,"class":45},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":19,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100562577","arginin-stimulated-copeptin-in-polyuria-polydipsia-syndrome-in-children-100562577","NCT06604975","Arginin-stimulated Copeptin in Polyuria-polydipsia Syndrome in Children","COPEPCHILD","Inclusion Criteria:\n\n* Children aged 2 to 18 years with polyuro-polydipsia syndrome (defined as hypotonic diuresis \\> 50 mL\u002Fkg\u002Fday in pediatric age or 30 mL\u002Fkg\u002Fday in late puberty (Tanner 5)) presenting for differential diagnosis between PP and DIC\n* Basal copeptin of less than 30 pmol\u002Fl\n* Agreeing to participate in the study\n* Whose two parents' consent to have their child participate in the study.\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Unbalanced dysthyroidism\n* Corticotropic deficiency\n* Ionic disorders (dysnatremia \\< 135 or \\> 145 mmol\u002Fl, dyskalemia \\< 3 or \\> 5 mmol\u002Fl, corrected dyscalcemia \\< 2.2 or \\> 2.6 mmol\u002FL)\n* Moderate to severe clinical dehydration (recent weight loss \\> 5% of body weight, clinical or biological signs of dehydration) requiring immediate therapeutic management\n* Renal failure with GFR \\< 60 mL\u002Fmin\u002F1.73 m2\n* Uropathy\n* Tumor syndrome (except hypothalamo-pituitary tumor)\n* Intracranial hypertension\n* ROHHAD syndrome\n* Fever or biological inflammatory syndrome with CRP \\> 5 mg\u002FL\n* Hepatic insufficiency\n* Contraindication to MRI\n* Contraindication to progressive water intake restrictions\n* History of contraindication to arginine\n* Positive test for Pregnancy\n* Lack of authorization by both parents or legal representatives","2 Years",{"count":81,"type":22},155,[58],"The exploration of polyuro-polydipsia syndrome (PPS) with hypotonic polyuria should distinguished, primary polydipsia (PP) due to excessive water intake, central diabetes insipidus (CDI) related to insufficient secretion of antidiuretic hormone (AVP), and nephrogenic diabetes insipidus (NDI) related to AVP insensitivity. The determination of plasma AVP is not relevant (unstable concentration, short in vitro half-life, long technical time and large blood sample). The differential diagnosis is currently based on a water deprivation test (WDT), an indirect reflection of AVP action, requiring more than 6 hours of hospitalization with risk of dehydration and low accuracy. Copeptin represents a new biomarker, direct mirror of AVP release with remarkable characteristics (stable, rapid determination, small blood volume). Copeptin has become a diagnostic tool in adult PPS and eliminated WDT in the diagnostic process. In children, basal copeptin values help for NDI and to exclude CDI (basal copeptin threshold \\> 30 and \\> 3.53 pmol\u002Fl (Se 100%, Sp 87.4%), respectively). Below 3.53 pmol\u002Fl, basal copeptin performance was inadequate to discriminate PP and CDI, highlighting the relevance of the stimulated copeptin study to improve this strategy. The arginine stimulation test is widely used as a simple, short duration (2 hours) and well tolerated tool to diagnose growth hormone deficiency in pediatrics. The performance of this test for copeptin stimulation was studied in adults with PPS with a high diagnostic accuracy.\n\nThe aim of the study is identify the best discriminant threshold of the arginine stimulation test in the uncertain diagnosis (basal copeptin \\\u003C30 pmol\u002Fl) in the polyuro-polydipsic syndrome in children.\n\nThen evaluate the discriminative capacities of the arginine stimulation test between the primary polydipsia and central insipid diabetes in the polyuro-polydipsic syndrome in children. And finally evaluate the cost-effectiveness of a new decisional algorithm for the differential diagnosis of PPS in children and evaluate the impact of infusion volume on copeptin secretion using the protidemia copeptin ratio.",[85,29,86],"Primary Polydipsia","Nephrogenic Diabetes Insipidus","NOT_YET_RECRUITING","2025-02-12",{"date":90,"type":38},"2025-02-13",{"date":92,"type":22},"2025-03",{"date":94,"type":22},"2028-07",{"name":96,"class":45},"Assistance Publique Hopitaux De Marseille",14]